Buckeye Surveillance, Contact, and Research for Multiple Myeloma and Amyloidosis
18 Years
N/A
Both
Plasma Cell Dyscrasias, Monoclonal Gammopathy of Undetermined Significance, AL Amyloidosis, Multiple Myeloma
Trial Information
Buckeye Surveillance, Contact, and Research for Multiple Myeloma and Amyloidosis
The investigators propose to contact and interact with all patients with plasma cell
dyscrasias in the State of Ohio (and all patients diagnosed or treated at Ohio State Medical
Center) for both surveillance and research purposes in order to develop interventions
targeted to decrease their morbidity and mortality.
Inclusion Criteria
Inclusion:
Diagnosis of a plasma cell dyscrasia
Exclusion:
Prisoners are excluded from participation as they have no standard access to the Ohio
State myeloma clinic and would impede the research objective of this protocol.
Type of Study:
Observational [Patient Registry]
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Develop a data and sample resource that can be used to facilitate research with the ultimate goal of reducing the morbidity and/or mortality of patients diagnosed or living with Multiple Myeloma in the state of Ohio
Outcome Time Frame:
up to 3 years
Safety Issue:
No
Principal Investigator
Craig C Hofmeister, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Ohio State University
Authority:
United States: Institutional Review Board
Study ID:
OSU - 10115
NCT ID:
NCT01408225
Start Date:
March 2011
Completion Date:
Related Keywords:
- Plasma Cell Dyscrasias
- Monoclonal Gammopathy of Undetermined Significance
- AL Amyloidosis
- Multiple Myeloma
- MGUS
- Multiple Myeloma
- Tissue Bank
- Amyloidosis
- Monoclonal Gammopathy of Undetermined Significance
- Paraproteinemias
- Multiple Myeloma
- Neoplasms, Plasma Cell
Name | Location |
|---|---|
| Ohio State University Medical Center | Columbus, Ohio 43210 |
